Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
NCT07019558

Ophthalmological Disorders in Dominant Spinal-cerebellar Ataxias

Led by University Hospital, Montpellier · Updated on 2025-11-20

60

Participants Needed

1

Research Sites

103 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Spinocerebellar ataxias (SCA) are rare genetic neurological disorders. The most common forms are SCA1, SCA2 and SCA3. Another more recently identified cause of ataxia is SCA27B. These are progressive, incapacitating pathologies, with adult onset (generally between 30 and 60 years of age) and progressive involvement. They are characterized by gait instability (ataxia), coordination disorders (dysmetria) and speech disorders (dysarthria). A complex disorder may also be present, with impaired ocular motility, double vision (diplopia) and difficulties with eye movements (ophthalmoplegia). In clinical practice, investigators have observed patients with advanced forms of SCA1 or SCA3 reporting a progressive decline in visual acuity. Other recent scientific observations confirm the possible presence of additional ophthalmological damage to the retina or optic nerve in SCA1, SCA2 and SCA3 pathologies. This study is a cross-sectional study, including subjects with SCA1, SCA2 and SCA3 at different stages of the disease, including the presymptomatic stage, with a complete and systematic study of visual damage. The same study will be applied to subjects with SCA27B in order to study the presence or absence of visual impairment, and possibly compare it with those of patients with polyglutamine-expanded SCA.

CONDITIONS

Official Title

Ophthalmological Disorders in Dominant Spinal-cerebellar Ataxias

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 80 years
  • Confirmed pathological expansion in ATXN1 (≥39 CAG), ATXN2 (≥33 CAG), or ATXN3 (≥45 CAG) genes for SCA1, SCA2, or SCA3 respectively, or pathological expansion (>250 GAA) in the FGF14 gene for SCA27B
  • Symptomatic with SARA score ≥4 or presymptomatic with SARA score <4
Not Eligible

You will not qualify if you...

  • Presence of systemic or eye diseases that affect the retina or eye examination, such as severe cataract or severe/decompensated diabetes
  • Visual acuity below 20/40, intraocular pressure >20 mmHg, cup to disc ratio >0.5, or severe refractive errors
  • Extremely severe neurological impairment preventing most eye examinations, such as inability to sit even with back support
  • Failure to obtain informed consent
  • Participants who have reached the maximum compensation for research participation
  • Not affiliated with a social security scheme
  • Persons under court protection
  • Currently taking part in other research studies

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

CHU Montpellier - Hôpital Gui de Chauliac

Montpellier, Hérault, France, 34000

Actively Recruiting

Loading map...

Research Team

C

Cecilia Marelli, PH

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here